ArticleOncoTargets and therapy2018

Adverse events risk associated with regorafenib in the treatment of advanced solid tumors: meta-analysis of randomized controlled trials.

Xiaonan Yin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.